Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Benzinga Newsdesk www.benzinga.com Negative 88.4%

Neg 88.4% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.